188 related articles for article (PubMed ID: 16126022)
1. Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA).
Sever PS; Poulter NR; Dahlöf B; Wedel H;
Am J Cardiol; 2005 Sep; 96(5A):39F-44F. PubMed ID: 16126022
[TBL] [Abstract][Full Text] [Related]
2. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
Sever PS; Poulter NR; Dahlof B; Wedel H;
J Hypertens; 2009 May; 27(5):947-54. PubMed ID: 19318984
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B;
Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):29-36. PubMed ID: 15703503
[TBL] [Abstract][Full Text] [Related]
4. The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K.
Sever PS; Chang CL; Gupta AK; Whitehouse A; Poulter NR;
Eur Heart J; 2011 Oct; 32(20):2525-32. PubMed ID: 21873710
[TBL] [Abstract][Full Text] [Related]
5. Lipid-lowering therapy and the patient with multiple risk factors: what have we learned from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)?
Sever PS
Am J Med; 2005 Dec; 118 Suppl 12A():3-9. PubMed ID: 16356801
[TBL] [Abstract][Full Text] [Related]
6. Impact of statin therapy on central aortic pressures and hemodynamics: principal results of the Conduit Artery Function Evaluation-Lipid-Lowering Arm (CAFE-LLA) Study.
Williams B; Lacy PS; Cruickshank JK; Collier D; Hughes AD; Stanton A; Thom S; Thurston H;
Circulation; 2009 Jan; 119(1):53-61. PubMed ID: 19103995
[TBL] [Abstract][Full Text] [Related]
7. The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure.
Sever PS; Poulter NR; Dahlof B; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes G; Mehlsen J; Nieminen MS; O'Brien ET; Ostergren J;
Eur Heart J; 2008 Feb; 29(4):499-508. PubMed ID: 18175773
[TBL] [Abstract][Full Text] [Related]
8. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
Sever PS; Dahlöf B; Poulter NR; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J;
Drugs; 2004; 64 Suppl 2():43-60. PubMed ID: 15765890
[TBL] [Abstract][Full Text] [Related]
9. Atorvastatin: gold standard for prophylaxis of myocardial ischemia and stroke - comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies.
Gresser U; Gathof BS
Eur J Med Res; 2004 Jan; 9(1):1-17. PubMed ID: 14766335
[TBL] [Abstract][Full Text] [Related]
10. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
Sever PS; Dahlöf B; Poulter NR; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J;
Lancet; 2003 Apr; 361(9364):1149-58. PubMed ID: 12686036
[TBL] [Abstract][Full Text] [Related]
11. Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial.
Nissen SE
Am J Cardiol; 2005 Sep; 96(5A):61F-68F. PubMed ID: 16126025
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
Mullins CD; Rattinger GB; Kuznik A; Koren MJ
Clin Ther; 2008; 30 Pt 2():2204-16. PubMed ID: 19281915
[TBL] [Abstract][Full Text] [Related]
13. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial.
Sever P; Dahlöf B; Poulter N; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen S; Kristinsson A; McInnes G; Mehlsen J; Nieminem M; O'Brien E; Ostergren J;
Eur Heart J; 2006 Dec; 27(24):2982-8. PubMed ID: 17145722
[TBL] [Abstract][Full Text] [Related]
14. Coronary heart disease benefits from blood pressure and lipid-lowering.
Sever PS; Poulter NR; Mastorantonakis S; Chang CL; Dahlof B; Wedel H;
Int J Cardiol; 2009 Jun; 135(2):218-22. PubMed ID: 19232755
[TBL] [Abstract][Full Text] [Related]
15. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention.
Zhou Z; Rahme E; Pilote L
Am Heart J; 2006 Feb; 151(2):273-81. PubMed ID: 16442888
[TBL] [Abstract][Full Text] [Related]
16. Atorvastatin: its clinical role in cerebrovascular prevention.
Gaspardone A; Arca M
Drugs; 2007; 67 Suppl 1():55-62. PubMed ID: 17910521
[TBL] [Abstract][Full Text] [Related]
17. Lipid lowering in hypertension and heart protection: observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) and the Heart Protection Study.
Nadar S; Lim HS; Beevers DG; Lip GY
J Hum Hypertens; 2002 Dec; 16(12):815-7. PubMed ID: 12522461
[No Abstract] [Full Text] [Related]
18. Perspectives from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial--Lipid Lowering Trial and the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm.
Brown WV; Moussa M
Curr Opin Lipidol; 2003 Dec; 14(6):593-7. PubMed ID: 14624136
[TBL] [Abstract][Full Text] [Related]
19. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): response to Server et al.
Tseng KH
Diabetes Care; 2005 Oct; 28(10):2595; author reply 2595-6. PubMed ID: 16186315
[No Abstract] [Full Text] [Related]
20. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States.
Foody JM; Joyce AT; Rudolph AE; Liu LZ; Benner JS
Clin Ther; 2008 Jan; 30(1):195-205. PubMed ID: 18343257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
